Journal
Future Oncology
Publication Date
11-1-2023
Volume
19
Issue
34
First Page
2277
Last Page
2289
Document Type
Open Access Publication
DOI
10.2217/fon-2023-0468
Rights and Permissions
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Recommended Citation
Oh, Do-Youn; Tan, Benjamin; and et al., "Plain language summary of the TOPAZ-1 study: Durvalumab and chemotherapy for advanced biliary tract cancer." Future Oncology. 19, 34. 2277 - 2289. (2023).
https://digitalcommons.wustl.edu/oa_4/2686
Department
ICTS (Institute of Clinical and Translational Sciences)
